EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 166 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,659 | -82.7% | 394 | -74.8% | 0.00% | -100.0% |
| Q1 2023 | $44,286 | +188.6% | 1,561 | +197.3% | 0.00% | – |
| Q4 2022 | $15,346 | +27.9% | 525 | +12.7% | 0.00% | – |
| Q3 2022 | $12,000 | -61.3% | 466 | -32.6% | 0.00% | -100.0% |
| Q2 2022 | $31,000 | +342.9% | 691 | +370.1% | 0.00% | – |
| Q1 2022 | $7,000 | +75.0% | 147 | +67.0% | 0.00% | – |
| Q4 2021 | $4,000 | -42.9% | 88 | -28.5% | 0.00% | – |
| Q3 2021 | $7,000 | +40.0% | 123 | +10.8% | 0.00% | – |
| Q2 2021 | $5,000 | +25.0% | 111 | +20.7% | 0.00% | – |
| Q1 2021 | $4,000 | 0.0% | 92 | -3.2% | 0.00% | – |
| Q4 2020 | $4,000 | 0.0% | 95 | 0.0% | 0.00% | – |
| Q3 2020 | $4,000 | +300.0% | 95 | +352.4% | 0.00% | – |
| Q2 2020 | $1,000 | – | 21 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |